This makes Aetna the first major insurer to cover these types of services.
CVS Health announced that it will provide coverage for intrauterine insemination (IUI) through its subsidiary Aetna, a managed health care company.1 This will provide patients covered by the company with the option to use IUI as a fertility test or as a way to increase chances of pregnancy. This makes Aetna the first major insurer to provide coverage for this procedure.
In a press release, Aetna chief medical officer and senior vice president Cathy Moffitt, MD, “Expanding IUI coverage is yet another demonstration of Aetna's commitment to women's health across all communities, including LGBTQ+ and unpartnered people. This industry-leading policy change is a stake in the ground, reflecting Aetna's support of all who need to use this benefit as a preliminary step in building their family."
Coverage for IUI will begin on September 1, 2024, and will be effective for most plans. According to CVS Health, plan sponsors will not need to make changes to their plans and the coverage will automatically be included in eligible plans.
Earlier this month, CVS Health announced that Heidi Capozzi had been named as an executive vice president and chief people officer and would be assuming the role on September 9 of this year.2
In a press release issued at the time, Capozzi said, "I am excited to join CVS Health and be part of a team whose strategy is bold and necessary: redefining how health care is delivered in this country. I admire CVS Health for its leadership in imagining and delivering a personalized health care experience, and I am proud to join a company that is truly colleague and customer focused with a mission dedicated to improving health for everyone."
In the same press release, CVS Health president and CEO Karen S. Lynch said, “Heidi brings a depth of experience and a breadth of industry insights to CVS Health, in particular a proven track record of hiring, building, and growing strong teams and advancing a winning culture. From nimble startups to established brands, Heidi has consistently applied her expertise to championing talent and we look forward to her being a part of our leadership team."
Also in August, CVS Health announced a new initiative to ensure access to medication and services during extreme weather events, such as extreme heat or major storms.3
In a press release, practicing physician and vice president and chief clinical innovation officer at CVS Caremark Dr. Dan Knecht said, “Extreme heat kills more Americans each year than all other weather events combined. In addition to fatalities driven by heat strokes, extreme heat can worsen chronic conditions such as cardiovascular disease, asthma and chronic obstructive pulmonary disease. Most heat-related deaths are preventable with outreach and intervention. We are proud to introduce a new capability that advances our efforts to find innovative ways to deliver personalized health care to consumers."
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
FDA Grants Priority Review to GSK’s Gepotidacin for Uncomplicated Urinary Tract Infections
October 18th 2024Priority Review status for GSK’s New Drug Application for gepotidacin was based on promising results from the Phase III EAGLE-2 and EAGLE-3 trials, which demonstrated non-inferiority to nitrofurantoin in uncomplicated urinary tract infections.